Figure 7.
Comparison of the VAF of mutations in patients with MPN-BP undergoing HCT with PB/BM blasts <5% vs those with active leukemia. Individual patients are ordered along the horizontal axis, with the VAFs for each mutation in that individual displayed along the vertical axis. Data points for MPN driver genes (JAK2, CALR, and MPL) are displayed in red, TP53 variants in blue, clonal hematopoiesis genes (DAT [DNMT3A, ASXL1, and TET2]) in green, and all other genes in black. The median VAF for MPN drivers, TP53, and DAT genes did not differ between patients with PB/BM blasts <5% vs those with active leukemia (drivers, 39.0 vs 30.3 [P = .64]; TP53, 9.7 vs 32.4 [P = .39]; DAT, 31.9 vs 27.2 [P = .47]; all, Mann-Whitney U test). In instances in which a gene was mutated more than once in a patient, the variant with the higher VAF was used for statistical analyses.

Comparison of the VAF of mutations in patients with MPN-BP undergoing HCT with PB/BM blasts <5% vs those with active leukemia. Individual patients are ordered along the horizontal axis, with the VAFs for each mutation in that individual displayed along the vertical axis. Data points for MPN driver genes (JAK2, CALR, and MPL) are displayed in red, TP53 variants in blue, clonal hematopoiesis genes (DAT [DNMT3A, ASXL1, and TET2]) in green, and all other genes in black. The median VAF for MPN drivers, TP53, and DAT genes did not differ between patients with PB/BM blasts <5% vs those with active leukemia (drivers, 39.0 vs 30.3 [P = .64]; TP53, 9.7 vs 32.4 [P = .39]; DAT, 31.9 vs 27.2 [P = .47]; all, Mann-Whitney U test). In instances in which a gene was mutated more than once in a patient, the variant with the higher VAF was used for statistical analyses.

Close Modal

or Create an Account

Close Modal
Close Modal